A Refractory Type Asthmatic Whose Symptoms Markedly Improved by Midaglizole

Abstract

We present a patient with refractory intrinsic asthma who showed a good response to both a single oral dose and a 4-week period of administration of the selective alpha-2 adrenoceptor antagonist, midaglizole. After the single dose, bronchodilation was immediately observed. With continuous administration, the peak expiratory flow rate (PEFR) was increased and the total daily intake of aerosol was decreased in a dose-dependent fashion. These results suggest that the addition of midaglizole to the usual antiasthmatic agents can be of value in the management of refractory asthma.